DexCom Inc DXCM

What the company does

DexCom Inc is a large-cap company in the Healthcare sector (Medical Devices), with a market value of $29.4B, based in the USA.

It employs about 11,000 people and has been listed since Apr 14, 2005.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 30.9 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 13% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 28.3 — they expect higher earnings.

The average analyst price target is 96.46, 24% above the current price (their view, not ours).

The stock sits at 62% of its one-year range (0% = the low, 100% = the high).

The risks

• • Quarterly report in 4 days (2026-10-29) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 19 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Buys back its shares (4% fewer shares in a year).
• ✅ More cash than debt.
• ✅ Most analysts rate it buy (26 vs 0).

What changed this week

Over the past week the stock fell 9.4% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? finance.yahoo.com · 2026-10-22
  What the article says

  DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The New England Journal of Medicine. The CONNECT study focused on adults with Type 2 diabetes who are not using insulin and assessed clinical outcomes with standalone real time CGM. Researchers… source ↗

• Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive? finance.yahoo.com · 2026-10-20
  What the article says

  Abbott Laboratories (NYSE:ABT) benefits each time a patient replaces a glucose sensor. Continuous glucose monitoring, or CGM, sales grew 9.5% excluding currency effects in the second quarter of 2026, versus 7.6% in the first quarter. The investment question is whether repeated purchases can sustain profitable growth… source ↗

• DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study finance.yahoo.com · 2026-10-20
  What the article says

  DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its Dexcom G7 continuous glucose monitoring (CGM) system in adults with Type 2 diabetes who are not using insulin, adding to the… source ↗

• Global Wearable Electronics Market Report 2026-2036 | AI, Extended Reality, and Digital Health Drive New Growth and Investment Opportunities finance.yahoo.com · 2026-10-19
  What the article says

  Company Logo Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- "The Global Wearable Electronics Market 2026-2036" has been added to ResearchAndMarkets.com's offering. The global wearable electronics market is undergoing a structural transformation as the industry expands beyond wrist-worn fitness trackers and smartwatches… source ↗

What changed since last week

• The price fell 9.4% since the last summary.